Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05877924Phase 1Recruiting

A Study of NBL-020 Injection in Subjects With Advanced Malignant Tumors.

Role: lead

NCT06223256Phase 1Recruiting

A Study of NBL-028 in Patients With Advanced Solid Tumors

Role: lead

NCT05259189Phase 1Completed

A Study of NBL-012 in Healthy Chinese Subjects

Role: lead

NCT05153096Phase 1Unknown

Evaluation of the Safety and Efficacy of NBL-015 in Patients With Advanced Solid Tumors

Role: lead

All 4 trials loaded